Literature DB >> 14521410

Identification and prediction of promiscuous aggregating inhibitors among known drugs.

James Seidler1, Susan L McGovern, Thompson N Doman, Brian K Shoichet.   

Abstract

Some small molecules, often hits from screening, form aggregates in solution that inhibit many enzymes. In contrast, drugs are thought to act specifically. To investigate this assumption, 50 unrelated drugs were tested for promiscuous inhibition via aggregation. Each drug was tested against three unrelated model enzymes: beta-lactamase, chymotrypsin, and malate dehydrogenase, none of which are considered targets of these drugs. To be judged promiscuous, the drugs had to inhibit all three enzymes, do so in a time-dependent manner, be sensitive to detergent and to enzyme concentration, and form particles detectable by light scattering. Of the 50 drugs tested, 43 were nonpromiscuous by these criteria. Surprisingly, four of the drugs showed promiscuous, aggregation-based inhibition at concentrations below 100 microM: clotrimazole, benzyl benzoate, nicardipine, and delavirdine. Three other drugs also behaved as aggregation-based inhibitors, but only at high concentrations (about 400 microM). To investigate possible structure-activity relationships among promiscuous drugs, five analogues of the antifungal clotrimazole were studied. Three of these, miconazole, econazole, and sulconazole, were promiscuous but the other two, fluconazole and ketoconazole, were not. Using recursive partitioning, these experimental results were used to develop a model for predicting aggregate-based promiscuity. This model correctly classified 94% of 111 compounds-47 aggregators and 64 nonaggregators-that have been studied for this effect. To evaluate the model, it was used to predict the behavior of 75 drugs not previously investigated for aggregation. Several preliminary points emerge. Most drugs are not promiscuous, even at high concentrations. Nevertheless, at high enough concentrations (20-400 microM), some drugs can aggregate and act promiscuously, suggesting that aggregation may be common among small molecules at micromolar concentrations, at least in biochemical buffers.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14521410     DOI: 10.1021/jm030191r

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  147 in total

1.  Design and synthesis of simplified taxol analogs based on the T-Taxol bioactive conformation.

Authors:  Jielu Zhao; Susan Bane; James P Snyder; Haipeng Hu; Kamalika Mukherjee; Carla Slebodnick; David G I Kingston
Journal:  Bioorg Med Chem       Date:  2011-10-13       Impact factor: 3.641

2.  Solubility at the molecular level: development of a critical aggregation concentration (CAC) assay for estimating compound monomer solubility.

Authors:  Jie Wang; Edmund Matayoshi
Journal:  Pharm Res       Date:  2012-03-16       Impact factor: 4.200

3.  Design and synthesis of nonpeptidic, small molecule inhibitors for the Mycobacterium tuberculosis protein tyrosine phosphatase PtpB.

Authors:  Katherine A Rawls; Christoph Grundner; Jonathan A Ellman
Journal:  Org Biomol Chem       Date:  2010-07-19       Impact factor: 3.876

4.  Self-assembling small molecules form nanofibrils that bind procaspase-3 to promote activation.

Authors:  Julie A Zorn; Holger Wille; Dennis W Wolan; James A Wells
Journal:  J Am Chem Soc       Date:  2011-11-17       Impact factor: 15.419

5.  Advances in Nuclear Magnetic Resonance for Drug Discovery.

Authors:  Robert Powers
Journal:  Expert Opin Drug Discov       Date:  2009-10-01       Impact factor: 6.098

Review 6.  Exploring biology with small organic molecules.

Authors:  Brent R Stockwell
Journal:  Nature       Date:  2004-12-16       Impact factor: 49.962

7.  Determining the optimal size of small molecule mixtures for high throughput NMR screening.

Authors:  Kelly A Mercier; Robert Powers
Journal:  J Biomol NMR       Date:  2005-03       Impact factor: 2.835

8.  Discovery of protein phosphatase 2C inhibitors by virtual screening.

Authors:  Jessica P Rogers; Albert E Beuscher; Marc Flajolet; Thomas McAvoy; Angus C Nairn; Arthur J Olson; Paul Greengard
Journal:  J Med Chem       Date:  2006-03-09       Impact factor: 7.446

Review 9.  Screening in a spirit haunted world.

Authors:  Brian K Shoichet
Journal:  Drug Discov Today       Date:  2006-07       Impact factor: 7.851

10.  Synergy and antagonism of promiscuous inhibition in multiple-compound mixtures.

Authors:  Brian Y Feng; Brian K Shoichet
Journal:  J Med Chem       Date:  2006-04-06       Impact factor: 7.446

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.